Type 2 Diabetes Clinical Trial
— ESCDMOfficial title:
Effectiveness of Share Care Diabetes Management in Patients With Type 2 Diabetes
This is a prospective, randomization, parallel, controlled study, which conducted to evaluate the effectiveness and related influencing factors of the Shared Care multidisciplinary diabetes care model. Patients with T2DM involved in the Shared Care model pay regularly quarterly visit to a multidisciplinary team led by physician at outpatient clinic, and receive remote and systematic management and education online after going home. After at least one year follow-up, evaluate the glycemic achieving rate (HbA1c<7%), the diabetes self-management behavior change and the effect of online diabetes self-management support for patients of the Shared Care multidisciplinary diabetes care model.
Status | Not yet recruiting |
Enrollment | 210 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients 18-80 years old diagnosed with type 2 diabetes - Patients who have Informed and signed the consent form content - Patients can be regularly followed (every 3 months) for at least 1 years Exclusion Criteria: - Patients with important organ failure or other severe diseases including infection, mentally disorder, heart failure or disseminated intravascular coagulation - Patients with active or inactive malignant tumour, expectation of life less than 1 year - Patients with communication disorders, cannot communicate and/or cooperate - Females that are regnant, breast-feeding female, or conception plan in the recent year |
Country | Name | City | State |
---|---|---|---|
China | Beijing Chao-Yang Hospital, Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Chao Yang Hospital |
China,
[A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China (author's transl)]. Zhonghua Nei Ke Za Zhi. 1981 Nov;20(11):678-83. Chinese. — View Citation
American Diabetes Association. (11) Children and adolescents. Diabetes Care. 2015 Jan;38 Suppl:S70-6. doi: 10.2337/dc15-S014. — View Citation
Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002 Oct 9;288(14):1775-9. — View Citation
Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002 Oct 16;288(15):1909-14. — View Citation
Internal Clinical Guidelines Team. Type 2 Diabetes in Adults: Management. London: National Institute for Health and Care Excellence (UK); 2015 Dec. — View Citation
International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation 8th edition; 2017
Ji LN, Lu JM, Guo XH, Yang WY, Weng JP, Jia WP, Zou DJ, Zhou ZG, Yu DM, Liu J, Shan ZY, Yang YZ, Hu RM, Zhu DL, Yang LY, Chen L, Zhao ZG, Li QF, Tian HM, Ji QH, Liu J, Ge JP, Shi LX, Xu YC. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013 Jun 21;13:602. doi: 10.1186/1471-2458-13-602. — View Citation
Pan XR, Yang WY, Li GW, Liu J. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care. 1997 Nov;20(11):1664-9. — View Citation
Wagner EH, Grothaus LC, Sandhu N, Galvin MS, McGregor M, Artz K, Coleman EA. Chronic care clinics for diabetes in primary care: a system-wide randomized trial. Diabetes Care. 2001 Apr;24(4):695-700. — View Citation
Wan EYF, Fung CSC, Jiao FF, Yu EYT, Chin WY, Fong DYT, Wong CKH, Chan AKC, Chan KHY, Kwok RLP, Lam CLK. Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses-A Population-Based and Propensity-Matched Cohort Study. Diabetes Care. 2018 Jan;41(1):49-59. doi: 10.2337/dc17-0426. Epub 2017 Nov 14. — View Citation
Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, Li Y, Zhao Z, Qin X, Jin D, Zhou M, Tang X, Hu Y, Wang L. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017 Jun 27;317(24):2515-2523. doi: 10.1001/jama.2017.7596. — View Citation
Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010 Mar 25;362(12):1090-101. doi: 10.1056/NEJMoa0908292. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Glycemic achieving rate | Glycemic achieving rate with HbA1c<7% at 1-year follow-up | through study completion, 1 year follow-up | |
Secondary | HbA1c change | Changes in HbA1c from baseline at 3, 6, and 12 months during follow-up | through study completion, 1 year follow-up | |
Secondary | Blood pressure change and rate of reaching the standard | Changes in blood pressure and the rate of reaching the standard (< 130/80) , including systolic blood pressure less than 130mmHg and diastolic blood pressure less than 80mmHg compared with the baseline at 3, 6, and 12 months respectively during follow-up. | through study completion, 1 year follow-up | |
Secondary | LDL-c changes and rate of reaching the standard | The changes of low density lipoprotein (LDL-c) compared with the baseline and the rate of reaching the standard (less than 2.6 mmol/L) at 3, 6, and 12 months during follow-up. | through study completion, 1 year follow-up | |
Secondary | BMI change and rate of reaching the standard | The changes of BMI from baseline and the rate of reaching the standard at 3, 6, and 12 months during follow-up. BMI is body mass index, weight and height will be combined to report BMI in kg/m^2 | through study completion, 1 year follow-up | |
Secondary | Medicine expenditure change | Patients' daily medicine expenditure (rmb / day) changed from baseline at 3, 6, and 12 months during follow-up | through study completion, 1 year follow-up | |
Secondary | SDSCA(Summary of Diabetes Self Care Activities) score change | The change between baseline SDSCA score and SDSCA score 1 years after admission, SDSCA is scale Summary of Diabetes Self Care Activities (SDSCA), with 12 questions, each provide a minimum of 0 and maximum of 7 scores (7 indicates better self care action), total score 84. | through study completion, 1 year follow-up | |
Secondary | C-DMSES(Chinese Diabetes Management Self-Efficacy Scale) score change | The change between baseline C-DMSES and C-DMSES 1 years after admission. C-DMSES is Chinese Diabetes Management Self-Efficacy Scale. The scale measures the self-efficacy level of diabetes management. The C-DMSES has 20 questions, each question has a minimum score of 0 (indicates lowest self-efficacy), maximum score of 10(indicates highest self-efficacy). the scale has totally 200 scores. | through study completion, 1 year follow-up | |
Secondary | A-DQOL(Amendment Diabetes Quality of Life scale) score change | The change between baseline A-DQOL score and A-DQOL score 1 years after admission. CA-DQOL has maximum score of 230. Subscale 1 measures life satisfaction and has 15 questions, each question has a minimum score of 1 (indicates very unsatisfied), maximum score of 5(indicates very satisfied). Subscale 2 measures frequency of diabetes affects life quality, has 20 questions, each question has a minimum score of 1 (indicates never affect life quality), maximum score of 5(indicates always affect life quality). Subscale 3 measures how much the patient worries about how diabetes affects daily life and has 7 questions, each question has a minimum score of 1 (indicates never worries), maximum score of 5(indicates very worries). Subscale 4 measures how much the patient worries about the diabetes-related conditions and has 4 questions, each question has a minimum score of 1 (indicates never worries), maximum score of 5(indicates very worries). | through study completion, 1 year follow-up | |
Secondary | Morisky scale score change | The change between baseline Morisky score and Morisky score 1 years after admission. Morisky scale measures patients' compliance of medication usage. The Morisky scale has 4 questions, each question has a minimum score of 0 (did not comply the medical instruction), maximum score of 1(comply medical instruction). the scale has totally 4 scores. | through study completion, 1 year follow-up | |
Secondary | DASS-C21 scale score change | The change between baseline DASS-C21 scale score and DASS-C21 scale score 1 years after admission. DASS-C21 scale is Depression Anxiety Stress Scale 21 scale in Chinese. The scale measures patients' level of depression, anxiety and stress. The scale has 21 questions, each question has a minimum score of 0 (did not meet the description), maximum score of 3(completely meet the description). the scale has totally 63 scores. | through study completion, 1 year follow-up | |
Secondary | Number of newly diagnosed diabetic complications | During the follow-up period, number of newly diagnosed diabetic complications, including diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and diabetic podiatry, etc. | through study completion, 1 year follow-up | |
Secondary | The progress of diabetic complications | During the follow-up period, the progress of diabetic complications such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and diabetic foot disease | through study completion, 1 year follow-up | |
Secondary | The times of Emergency visits due to hyperglycemia | During the follow-up period, the times of Emergency visits due to hyperglycemia were collected during each follow-up. | through study completion, 1 year follow-up | |
Secondary | The times of Emergency visits due to hypoglycemia | During the follow-up period, the times of Emergency visits due to hypoglycemia were collected during each follow-up. | through study completion, 1 year follow-up | |
Secondary | The times of Hospitalization due to hyperglycemia | During the follow-up period, the times of hospitalization due to hyperglycemia were collected during each follow-up. | through study completion, 1 year follow-up | |
Secondary | The times of Hospitalization due to hypoglycemia | During the follow-up period, the times of hospitalization due to hypoglycemia were collected during each follow-up. | through study completion, 1 year follow-up | |
Secondary | The days of Hospitalization due to hyperglycemia | During the follow-up period, the days of hospitalization due to hyperglycemia were collected during each follow-up. | through study completion, 1 year follow-up | |
Secondary | The days of Hospitalization due to hypoglycemia | During the follow-up period, the days of hospitalization due to hypoglycemia were collected during each follow-up. | through study completion, 1 year follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |